What Chonluten Is
Chonluten is a synthetic tripeptide, Thr-Glu-Asp (TED), classified within the peptide bioregulator family as associated with bronchial mucosa and respiratory epithelium.
It is one of only two members of the family built on a threonine N-terminus; the rest of the catalog is dominated by lysine- and alanine-initiated sequences. That structural difference is real and verifiable, and it is about as far as verifiable statements about this compound go.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists in any jurisdiction and no therapeutic claim is made.
A Note on the Structural Record
Accuracy about structure is the minimum a supplier owes a researcher, so this is worth documenting: our own catalog previously carried a molecular formula for Chonluten that did not correspond to the Thr-Glu-Asp sequence. It has been corrected.
The correct values, confirmed against PubChem CID 145458042 and by independent calculation from the constituent residues, are C13H21N3O9 at 363.32 g/mol. If you sourced material against the earlier figure, verify the certificate of analysis for the batch you hold.
What the Published Literature Contains
No PubMed-indexed study names Chonluten in its title. There is no compound-specific work establishing an effect on respiratory epithelium, a mechanism specific to Thr-Glu-Asp, a safety profile, or an amount for any species.
The literature commonly cited alongside this compound is class-level: peptide regulation of gene expression (PMID 34834147), short peptides regulating gene expression (PMID 27909961), and peptides regulating proliferative and inflammatory pathways in a monocyte/macrophage cell line (Avolio et al., Int J Mol Sci 2022, PMID 35408963).
These describe the family. None is a study of TED, and the respiratory association attributed to Chonluten comes from the family's own classification scheme rather than from a published experiment on this sequence.
Why the Gap Is Worth Knowing
The absence of literature is not evidence that the compound is inert. It is evidence that no one has published a test. For a researcher, that distinction determines what the compound is good for: it cannot serve as a positive control or a benchmark, but it is a legitimate subject if the question is characterising an unstudied sequence within a family that has a stated mechanistic hypothesis.
Structure and Handling
- Sequence. Thr-Glu-Asp (TED), tripeptide.
- Formula. C13H21N3O9, 363.32 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
Related Compounds
Bronchogen (Ala-Glu-Asp-Leu) carries the same respiratory association within the family and has one paper naming it. For compounds with substantive published work see Vilon, Pancragen and Epithalon. The full family sits on our bioregulator overview.
The Class Evidence Base: What Short Peptide Bioregulator Studies Actually Show — and What They Do Not
Because no PubMed-indexed study has investigated Thr-Glu-Asp specifically, any researcher evaluating Chonluten must work from class-level evidence and assess how much of it can reasonably be extrapolated to this compound. The short answer is: less than is commonly assumed, and the table below is constructed to make that boundary visible rather than to obscure it.
The peptide bioregulator literature — principally the output of the St. Petersburg Institute of Bioregulation and Gerontology — describes effects of di- and tripeptides on gene transcription, proliferation, and inflammatory signaling. The operative proposed mechanism, published across several papers from this group, is direct or indirect interaction between short peptides and regulatory DNA sequences, potentially modulating promoter accessibility.[4] This is a real and active area of chromatin biology, and the general claim that short peptides can influence gene expression is not implausible. The specific claim that TED acts via this mechanism on respiratory epithelium has not been tested.
| Study / Year | Model | Compound Tested | Key Finding | Applicability to TED | PMID |
|---|---|---|---|---|---|
| Khavinson et al., 2016 | Computational / cell-free binding assay | Class: di- and tripeptides (not TED) | Short peptides proposed to intercalate with promoter DNA sequences; sequence-dependent selectivity modeled | Indirect — establishes class mechanism only; TED sequence not among compounds modeled | 27909961 |
| Khavinson et al., 2022 | Human cohort, aging biomarkers | Class: peptide bioregulator preparations (mixed) | Association reported between peptide bioregulator use and epigenetic aging markers; no compound-level disaggregation | Indirect — compound identity not resolvable from published data | 34834147 |
| Avolio et al., 2022 | In vitro: THP-1 monocyte/macrophage line | Short regulatory peptides (class) | Modulation of proliferative and inflammatory pathway markers observed; effect magnitudes and specific peptides not fully disclosed in abstract | Indirect — respiratory epithelium is a different cell type; TED not individually named | 35408963 |
⚠️ Epistemic note: Every row in this table describes class-level or mixed-compound evidence. No row documents a measurement made on Thr-Glu-Asp. A researcher who requires compound-specific pharmacodynamic data before proceeding will find that data does not yet exist in the indexed literature. That is the correct finding, not a gap to be bridged by inference.
Structural Comparison with Related Peptide Bioregulators
Placing Chonluten within the bioregulator family by structure rather than by marketing classification reveals both its distinctiveness and the limits of cross-compound extrapolation. The three compounds below represent the closest structural neighbors for which identity data are independently verifiable.
| Compound | Sequence | Formula | MW (g/mol) | N-terminal residue | Tissue association (per developer classification) | PubChem CID |
|---|---|---|---|---|---|---|
| Chonluten | Thr-Glu-Asp (TED) | C₁₃H₂₁N₃O₉ | 363.32 | Threonine | Bronchial mucosa / respiratory epithelium | 145458042 |
| Bronchogen | Ala-Glu-Asp-Leu (AEDL) | C₁₈H₂₉N₄O₈⁺ (as salt forms vary) | ~430 (free acid) | Alanine | Bronchial epithelium / lung | Verify independently |
| Vilon | Lys-Glu (KE) | C₁₁H₂₁N₃O₅ | 275.30 | Lysine | Thymus / immune | Verify independently |
| Epithalon | Ala-Glu-Asp-Gly (AEDG) | C₁₄H₂₂N₄O₉ | 390.34 | Alanine | Pineal / neuroendocrine | 135449039 |
Several observations follow from this structural alignment and are worth making explicit for researchers designing experiments:
Sequence divergence vs. shared tissue association. Chonluten and Bronchogen are both developer-classified as bronchial-associated, yet they differ in sequence length (tripeptide vs. tetrapeptide), N-terminal residue (Thr vs. Ala), and total mass. If tissue selectivity were sequence-determined in a simple way, these two compounds should not share a target classification; if it is not sequence-determined, the classification system's mechanistic basis requires explicit justification that the published record does not currently provide.[4]
Threonine as N-terminus. Chonluten is unusual within this catalog in beginning with threonine, a β-hydroxyl-bearing residue with distinct hydrogen-bonding geometry compared to alanine or lysine. Whether this confers any functional difference in proposed DNA-binding or receptor interactions is, as of the indexed literature, untested for this compound.
Cross-compound extrapolation is not supported. The existence of human or animal data for Bronchogen or Epithalon does not constitute evidence for Chonluten, even where the proposed tissue target overlaps. Researchers should treat each compound as requiring its own evidence base until compound-specific data exist.[4]
Formula and mass values for Chonluten are confirmed against PubChem CID 145458042. Researchers are advised to verify CIDs for Bronchogen and Vilon independently, as salt forms and counterion conventions affect reported molecular weights across databases.
